Year |
Citation |
Score |
2023 |
Howard T, Almieda M, Diego V, Viel K, Luu B, Haack K, Raja R, Ameri A, Chitlur M, Rydz N, Lillicrap D, Watts R, Kessler C, Ramsey C, Dinh L, et al. A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A. Research Square. PMID 37886476 DOI: 10.21203/rs.3.rs-3371095/v1 |
0.325 |
|
2014 |
Viel KR, Kim B, Tejero ME, Cole SS, Howard TE, Ortiz AS. The Spectrum of Amino Acid Substitutions Resulting from Single Nucleotide Substitutions in the Coagulation Biosystem: Impact on Identification By Mass Spectrometry Blood. 124: 4221-4221. DOI: 10.1182/Blood.V124.21.4221.4221 |
0.337 |
|
2013 |
Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nature Medicine. 19: 1318-24. PMID 24037092 DOI: 10.1038/Nm.3270 |
0.368 |
|
2012 |
Howard TE, Drigalenko E, Johnson MP, Cole SS, Kim B, Viel KR, Sauna ZE, Curran JE, Blangero J, Almasy LA, Göring HH. Common SNPs within or near Three Immune Response Genes Implicated in the Risk of FVIII Immunogenicity in Hemophilia A Do Not Influence Steady-State Levels of Their Encoded mRNAs Blood. 120: 3366-3366. DOI: 10.1182/Blood.V120.21.3366.3366 |
0.428 |
|
2012 |
Kim B, Sauna ZE, Carless MA, Curran JE, Viel KR, Cole SS, Raja R, Blangero J, Howard TE. F8 and HLA-II Haplotypes in the Hispanic Population: Implications for Inhibitor Risk Development in Hispanic Hemophilia A Patients Blood. 120: 3365-3365. DOI: 10.1182/Blood.V120.21.3365.3365 |
0.403 |
|
2011 |
Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, Pratt KP. Haemophilia management: time to get personal? Haemophilia : the Official Journal of the World Federation of Hemophilia. 17: 721-8. PMID 21649795 DOI: 10.1111/J.1365-2516.2011.02517.X |
0.337 |
|
2010 |
Howard TE, Viel KR, Drigalenko E, Cole S, Epstein M, Carless M, Hughes R, Kim B, Dyer T, Pratt KP, MacCluer JW, Curran JE, Johnson MP, Moses EK, Blangero J, et al. No Evidence of Cis-Acting SNPs In Immune Response Genes Previously Associated with Factor VIII Inhibitors: The San Antonio Family Heart Study Blood. 116: 4422-4422. DOI: 10.1182/Blood.V116.21.4422.4422 |
0.422 |
|
2009 |
Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII in black patients with hemophilia. The New England Journal of Medicine. 360: 1618-27. PMID 19369668 DOI: 10.1056/Nejmoa075760 |
0.341 |
|
2007 |
Viel KR, Machiah DK, Warren DM, Khachidze M, Buil A, Fernstrom K, Souto JC, Peralta JM, Smith T, Blangero J, Porter S, Warren ST, Fontcuberta J, Soria JM, Flanders WD, et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood. 109: 3713-24. PMID 17209060 DOI: 10.1182/Blood-2006-06-026104 |
0.516 |
|
2007 |
Viel KR, Howard T, Curran JE, Almasy L, Moses EK, Glahn DC, Ameri A, John B. Heritability of Commonly Measured Blood Cell Phenotypes in the San Antonio Family Heart Study. Blood. 110: 3687-3687. DOI: 10.1182/Blood.V110.11.3687.3687 |
0.345 |
|
2006 |
Khachidze M, Buil A, Viel KR, Porter S, Warren D, Machiah DK, Soria JM, Souto JC, Ameri A, Lathrop M, Blangero J, Fontcuberta J, Warren ST, Almasy L, Howard TE. Genetic determinants of normal variation in coagulation factor (F) IX levels: Genome-wide scan and examination of the FIX structural gene Journal of Thrombosis and Haemostasis. 4: 1537-1545. PMID 16839351 DOI: 10.1111/J.1538-7836.2006.02024.X |
0.449 |
|
2006 |
Howard TE, Viel KR, Fernstrom KM, Deshpande S, Ameri A, Ali MS, Channell C, Iyer RV, Watts RG, Lutcher C, Nakaya S, Kasper CK, Thompson AR, Abshire TC, Almasy L. Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent. Blood. 108: 765-765. DOI: 10.1182/Blood.V108.11.765.765 |
0.403 |
|
2006 |
Viel KR, Khachidze M, Almasy L, Thompson AR, Howard TE. Potential Spectrum of Missense and Nonsense Factor (F)VIII Gene (F8) Alleles Based on Single Nucleotide Substitutions - How Many Remain To Be Identified?. Blood. 108: 4039-4039. DOI: 10.1182/Blood.V108.11.4039.4039 |
0.427 |
|
2005 |
Bickeböller H, Bailey JN, Papanicolaou GJ, Rosenberger A, Viel KR. Dissection of heterogeneous phenotypes for quantitative trait mapping. Genetic Epidemiology. 29: S41-7. PMID 16342183 DOI: 10.1002/Gepi.20109 |
0.363 |
|
2005 |
Howard TE, Machiah DK, Viel KR, Channel C, Ameri A, Iyer RV, Watts RG, Lutcher C, Davis J, Abshire TC, Almasy L. The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients. Blood. 106: 3207-3207. DOI: 10.1182/Blood.V106.11.3207.3207 |
0.435 |
|
2004 |
Viel KR, Khachidze M, Buil A, Soria JM, Souto JC, Fontcuberta J, Blanco-Vaca F, Ordoñez-Llanos J, Almasy L, Tom H. A Quantitative Trait Locus for Cholesterol/Low Density Lipoprotein within the Promoter of the Factor IX Gene. Blood. 104: 4000-4000. DOI: 10.1182/Blood.V104.11.4000.4000 |
0.35 |
|
2004 |
Howard T, Machiah DM, Tran TT, Viel KR, Channell C, Soria JM, Ameri A, Iyer RV, Brown C, Doering C, Almasy L, Watts R, Davis J, Abshire TC. African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development?. Blood. 104: 384-384. DOI: 10.1182/Blood.V104.11.384.384 |
0.41 |
|
Show low-probability matches. |